We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Zynlonta was granted FDA accelerated approval in April 2021 as a single-agent intravenous treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. Read More
Bristol Myers Squibb (BMS) has settled with Alembic Pharmaceuticals over allegations that Alembic’s proposed generic drug infringed on its blockbuster blood cancer drug Revlimid (lenalidomide). Read More
AstraZeneca is buying TBio subsidiary TeneoTwo, which will shore up its hematology pipeline with TeneoTwo’s candidate for relapsed and refractory B-cell non-Hodgkin lymphoma. Read More
Novartis said it has resumed operations at its Millburn, N.J., and Ivrea, Italy, plants after recently halting production over quality lapses related to the manufacture of radioligand therapy medicines. Read More
Sanofi will begin offering 30-day supplies of its insulin products to uninsured patients in the U.S. for $35 on July 1, the company announced Wednesday. Read More
Molecure said it is considering going back to its original plan, which was to develop OATD-01 for treatment of the inflammatory disease sarcoidosis. Read More